Skip to content

Safety and Efficacy of Combined DEB-BACE and Bronchoscopic Intervention for Advanced Central Squamous Cell Lung Carcinoma with Airway Stenosis Failing Chemoradiotherapy

Safety and Efficacy of Combined DEB-BACE and Bronchoscopic Intervention for Advanced Central Squamous Cell Lung Carcinoma with Airway Stenosis Failing Chemoradiotherapy: A Single-Center Prospective Clinical Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600115911
Enrollment
Unknown
Registered
2026-01-04
Start date
2026-01-15
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Central Squamous Cell Lung Carcinoma with Airway Stenosis Failing Chemoradiotherapy

Interventions

Advanced Central Squamous Cell Lung Carcinoma with Airway Stenosis:None

Sponsors

Huzhou Center Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1.Aged 18–90 years; 2.Clinically, histopathologically, and radiologically (CT) confirmed diagnosis of advanced-stage central squamous cell lung carcinoma (SCC) with concurrent airway stenosis; TNM stage III or IV; patients deemed ineligible for or refusing surgical resection; 3.At least one measurable target lesion (per RECIST 1.1 or similar standard criteria); 4.Intolerance to chemoradiotherapy or documented disease progression following chemoradiotherapy; 5.Life expectancy > 3 months; 6.Provision of written informed consent after being fully informed about the study.

Exclusion criteria

Exclusion criteria: 1.Pregnancy, lactation, or planned pregnancy in patients of childbearing potential; 2.Severe cardiac, pulmonary, hepatic, or renal insufficiency; or clinically significant uncorrectable coagulopathy; 3.Extensive or uncontrolled extrapulmonary metastatic disease; 4.Concurrent active malignancy of another organ system or severe systemic immune disorder; 5.Contraindications to vascular intervention, bronchoscopic intervention, or iodinated contrast media; 6.Severe uncontrolled recurrent infections or other significant uncontrolled comorbidities; 7.Concurrent participation in another clinical trial or any other condition deemed unsuitable for enrollment by the investigator (due to safety concerns or protocol non-adherence);

Design outcomes

Primary

MeasureTime frame
Improvement in Airway Stenosis;Control of Airway Hemorrhage;;Oncologic Treatment Efficacy;Control of Airway Hemorrhage;

Countries

China

Contacts

Public ContactShen Bin

Huzhou Center Hospital

18657258281@163.com+86 572 255 5751

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026